ARS rises on positive trial result for urticaria treatment

ARS Pharmaceuticals

26/02/2024 14:57

** Shares of drug developer ARS Pharmaceuticals  SPRY.O 
rise 4.1% to $8.73, its highest since May 2023
    ** Co says its nasal spray neffy, in a mid-stage trial, 
showed statistically significant and clinically meaningful
improvement in patients with a form of urticaria
    ** Urticaria is a common skin disorder characterized by
itchy rashes and swelling beneath the skin
    ** Including session's move, stock up 1% in the last 12
months


    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))